Estratetraenol

An endogenous estrane steroid studied almost entirely as a putative female-associated human chemosignal rather than as a classical hormone.

Estratetraenol has not been evaluated in formal toxicology, chronic exposure, or systemic pharmacokinetic studies, and there is no established therapeutic or supplemental use. In human research it is applied only as a trace, near-threshold odorant, typically a small quantity dissolved in a carrier such as propylene glycol and smelled briefly, and no adverse effects have been reported at these minute concentrations. Because it is essentially non-estrogenic and is presented in vanishingly small amounts, it is not expected to exert hormonal effects through the bloodstream, but this has not been directly characterized in controlled safety trials. It should be regarded as an experimental research substance rather than a product with any validated safety profile for ingestion, topical application, or repeated use.

Estratetraenol was chemically identified in 1968 by Thysen, Elliott, and Katzman, who isolated it from the urine of pregnant women, establishing it as an endogenous human steroid. It attracted little attention for decades until the surge of interest in candidate human pheromones in the 1990s and 2000s, when it was paired conceptually with androstadienone (a steroid enriched in male sweat and semen) and cast as a female-associated signal.

Early mood and physiology work by Jacob and McClintock and colleagues examined steroidal chemosignals in context-dependent settings, and a widely cited 2014 study by Zhou and colleagues in Current Biology reported that estratetraenol biased gender perception in heterosexual men but not women, catalyzing a wave of follow-up experiments on cooperation, sexual cognition, emotional perception of biological motion, and interactions with intranasal oxytocin. Over the same period, critics such as Wyatt argued that the field had never met the rigorous bioassay standard used to define pheromones in other species, and controlled double-blind attempts, including work by Hare and colleagues in 2017, failed to reproduce several of the headline effects.

Within the chemosensory and social neuroscience communities, estratetraenol is regarded as a prominent but unproven candidate human chemosignal rather than an accepted pheromone. Proponents point to a cluster of studies reporting sexually dimorphic effects on gender judgment, mood, cooperative behavior, and hypothalamic activation, while skeptics emphasize small samples, publication bias, and failed replications, and note that neither estratetraenol nor androstadienone was ever isolated through the bioassay-guided approach that defines pheromones in other animals.

Reviews by Wyatt and commentary in the chemistry press have repeatedly flagged the compound as emblematic of a field that outran its evidence. In nootropic and supplement circles it has essentially no presence, as it is not sold or used for cognitive or hormonal benefit; its reputation is almost entirely academic and centers on the open question of whether humans communicate chemically at all.